Compare PRAX & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | G |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | Bermuda |
| Employees | N/A | 140000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.2B |
| IPO Year | 2020 | 2007 |
| Metric | PRAX | G |
|---|---|---|
| Price | $302.17 | $38.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $572.13 | $49.50 |
| AVG Volume (30 Days) | 317.3K | ★ 1.9M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.96% |
| EPS Growth | N/A | ★ 9.82 |
| EPS | N/A | ★ 3.13 |
| Revenue | N/A | ★ $2,279,438,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,395.88 | $7.26 |
| P/E Ratio | ★ N/A | $12.23 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.70 | $34.79 |
| 52 Week High | $354.87 | $51.28 |
| Indicator | PRAX | G |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 45.26 |
| Support Level | $290.36 | $37.58 |
| Resistance Level | $322.32 | $40.44 |
| Average True Range (ATR) | 16.31 | 1.03 |
| MACD | -3.55 | 0.04 |
| Stochastic Oscillator | 28.40 | 29.19 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.